SAN FRANCISCO, November 11, 2001 Data from a Phase 2 clinical study of ENBREL (etanercept) in ankylosing spondylitis will be presented this week at the 65th Annual Scientific Meeting of the American College of Rheumatology. This study, conducted by Dr. John Davis and colleagues at the University of California, San Francisco, is the first randomized, placebo-controlled study of ENBREL for the treatment of ankylosing spondylitis. Phase 2 results showed that 80 percent of 20 patients receiving ENBREL reached the primary composite endpoint of improvement compared to 30 percent of 20 patients receiving placebo.
"This is pioneering work in ankylosing spondylitis, says Jane Bruckel, Executive Director, Spondylitis Association of America. The community looks forward to additional data from the new study."
In the Phase 2 double-blind, placebo-controlled study, 40 patients with ankylosing spondylitis were randomized to receive either 25 mg of ENBREL via subcutaneous (under the skin) injection or placebo twice per week for a four-month period.
The primary endpoint was a comparison of the number of patients achieving a clinical response in the ENBREL and placebo groups. A clinical response was prespecified as a ?20 percent improvement in three of five outcome measures (duration of morning stiffness, nocturnal spinal pain, a functional index (BASFI), patient global assessment and swollen joint score).
Eligible patients fulfilled the modified New York clinical criteria for ankylosing spondylitis, and were required to have evidence of active spondylitis, which was defined as presence of inflammatory back pain, morning stiffness equal to or greater than 45 minutes, and patient and physician global assessment of moderate or higher disease activity. Patients were able to continue nonsteroidal anti-inflammatory drugs (NSAIDs), prednisone and disease modifying anti-rheumatic drugs (DMARDs) at stable dosages during the trial.
Result
'"/>
12-Nov-2001
Page: 1 2 3 4 Related biology news :1.
Phase II trials of second-generation antisense cancer drug planned following successful early study2.
OneWorld Health completes enrollment, treatment in Phase III India trial3.
Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins4.
VaxGen reports Phase I clinical trial results of anthrax vaccine candidate5.
Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound6.
KEPPRA international Phase IV SKATE study results show favourable efficacy7.
Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting8.
Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today9.
OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug10.
Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair11.
Phase transition in bilayers could affect their performance